Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04977336 · ClinicalTrials.gov registry record · Phase 2

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

A Phase 2 study of Acute Pain, sponsored by Vertex Pharmaceuticals Incorporated.

Completed
Registry status
Phase 2
Development phase
274
Enrollment target
12
Study locations

NCT04977336: Completed Phase 2 study of Acute Pain, sponsored by Vertex Pharmaceuticals Incorporated.

NCT04977336 is a Phase 2 study of Acute Pain that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 274 participants, roughly in line with the 263-participant average among 50 other Acute Pain trials with a reported enrollment target. The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04977336, a Phase 2 study of Acute Pain, has completed, sponsored by Vertex Pharmaceuticals Incorporated.

COMPLETED
Registry status
Phase 2
Development phase
274 participants
Enrollment target
12
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after a bunionectomy.

Primary Outcome

SPID was calculated as the sum of the product of time (in hours) elapsed since previous measurements and pain intensity difference. Pain intensity difference was calculated by subtracting the pain intensity score at given post-dose time points from the baseline pain intensity scores (using pain rating score range: 0= no pain to 10= worst possible pain). SPID48 was calculated from 0 to 48 hours and the score range was -480 (worst score) to 480 (best score).

Conditions Studied

Interventions

  • DRUG VX-548
  • DRUG HB/APAP
  • DRUG Placebo (matched to VX-548)
  • DRUG Placebo (matched to HB/APAP)

Study Locations (12)

California

  • Anaheim Clinical Trials - Anaheim
  • Lotus Clinical Research - Pasadena
  • New Hope Research Development - Tarzana

Texas

  • First Surgical Hospital - Bellaire
  • Legent Orthopedic Hospital - Carrollton
  • Endeavor Clinical Trials - San Antonio

Alabama

  • Shoals Medical Trials Inc. - Sheffield

Arizona

  • Arizona Research Center - Phoenix

Georgia

  • Atlanta Center for Medical Research - Atlanta

Maryland

  • Chesapeake Research Group - Pasadena

Ohio

  • Midwest Clinical Research Center - Dayton

Utah

  • JBR Clinical Research - Salt Lake City

Trial Details

FieldValue
Enrollment Target 274 participants
Start Date 2021-07-19
Est. Completion 2022-03-04
Phase Phase 2
Vertex Pharmaceuticals Incorporated

191 total trials

What the finished NCT04977336 record still lists

NCT04977336 is an interventional study that assigns participants to a tested intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 263-participant average among 50 other Acute Pain trials with a reported enrollment target.

The record links to 1 condition, with Acute Pain appearing as the primary indexed condition, and to 4 interventions - of which VX-548 is the first listed.

NCT04977336 lists 12 locations in 8 states (California, Texas, Alabama).

Frequently Asked Questions

What is clinical trial NCT04977336 about?

NCT04977336 is a clinical study titled "A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy". The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after a bunionectomy.

What is the current status of trial NCT04977336?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2021-07-19. Estimated completion is 2022-03-04.

What conditions does trial NCT04977336 study?

This clinical trial studies the following conditions: Acute Pain.

What interventions are being tested in trial NCT04977336?

The interventions under investigation include: VX-548 (DRUG), HB/APAP (DRUG), Placebo (matched to VX-548) (DRUG), Placebo (matched to HB/APAP) (DRUG).

Who is sponsoring clinical trial NCT04977336?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04977336 being conducted?

This trial has 12 study locations across Alabama, Arizona, California, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04977336's enrollment target sits among peer trials

274 12th of 50 higher than 39 of 50 other Acute Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03808922 · 274 participants · Phase 3

    Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

  • NCT04573504 · 274 participants · Phase 4

    Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair

  • NCT05289557 · 274 participants · Phase 3

    The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

  • NCT05952583 · 274 participants

    Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04977336, the US trial registry maintained by the National Library of Medicine. NCT04977336 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.